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Abstract
Stat5, c-myc, Hipk2, Fiz1, and ZFP521 to lymphomagenesis precursor B-cell lymphoblastic 
lymphoma/leukemia have been previously identified as a putative gene involved in the 
induction of B-cell lymphomagenesis. In this review, we summarize the role of ZFP521 in 
B-cell lymphomagenesis. Zinc finger protein 521 (Zfp521) is a novel identified gene that 
is responsible for pre–B-lymphoblastic lymphomagenesis through activation of pre–B-cell 
receptor (pre-BCR)-signaling by upregulation of adaptor genes and related kinases in the 
signaling downstream. The pre-BCR-signaling molecules, FLT3, CD43, and IL-7 receptor 
(IL-7R) were positively regulated by these genes. Stimulation of pre-BCR and/or IL-7R 
signaling caused aberrant upregulation of other oncogene sets such as cyclin genes, thereby 
inducing the growth of pre–B cells. IL-7R/Janus kinase (JAK)/STAT signaling cascade is one 
of the key signaling pathways that are activated in precursor B-cell lymphoblastic lymphoma/
leukemia. FLT3, CD43, and pre-BCR cascades crosstalk with JAK/STAT cascade. FLT3 and 
CD43 cascades have the potential to enhance JAK/STAT cascade effect on pre-B cell growth. 
On the other hand, pre-BCR and interleukin (IL)-7 receptor exerted competitive effects on 
pre–B-cell growth; thus, precursor B-cell lymphoblastic lymphomagenesis is a consequence 
through interaction with these cascades.
Keywords: pre–B-cell receptor, Stat/Jak pathway, Zfp521
1. Introduction
1.1. Summary
B-cell lymphoblastic leukemia/lymphoma (B-LBL) is a neoplasm that exhibits immature phe-
notype of the B-cell lineage with on-going immunoglobulin rearrangement. Understanding the 
activation of signal pathways in tumor cells provides significant knowledge on tumorigenesis. 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Surface markers interleukin-7 receptor (IL-7R), FLT3, CD43, and phenotypic marker pre–B-cell 
receptor are aberrantly activated in tumor cells. IL-7R is one of the developmental stage mark-
ers and is closely associated with immunoglobulin gene rearrangement in mice. In addition, 
these IL-7R, FLT3, and CD43 signal pathways interact with each other. The signaling molecules, 
JAK3, Stat5a, Fiz1, and Hipk2, play pivotal roles in these signaling pathways. In this review, we 
summarize the activation networks of these pathways from the perspective of the activation of 
adaptor molecules and immunoglobulin rearrangement.
1.2. Introduction
B-LBL is a neoplasm of B-lymphoid precursors and it is essentially identical to acute lympho-
cytic leukemia as it involves the bone marrow and peripheral blood [1, 2]. These lymphomas 
and leukemias are composed of medium-sized blast cells with scant cytoplasm, an oval nucleus, 
transparent nucleus, condensed chromatin, and often multiple nucleoli. The lymphoma tissues 
exhibit mitotic figures and are phagocytosed by macrophages after apoptosis—this histology is 
called “Starry sky” and is well known in Burkitt lymphoma. Distinguishing B-precursor types 
from T-precursor types is impossible because they share similar cytological features. Immuno-
phenotypes of pre–B LBL resemble the normal immature B-cell lineages, primarily including 
pre–B cells, because pre–B LBL consists of ongoing immunoglobulin gene (Ig) rearrangements of 
heavy chains (Igh) or light chains (Igl). This rearrangement depends on the activity of recombina-
tion-activating gene 1 (RAG1) and RAG2 under the high expression of the interleukin 7 receptor 
(IL-7R) [3]. In addition, pre–B receptors consist of lambda5 and Vpreb component, which are 
surrogate light-chain components at the time of completion of Igh rearrangement (Figure 1) [4, 5].
2. The characterization of spontaneous pre–B-cell lymphoma in SL/Kh 
mice
2.1. Experimental mouse model of spontaneous lymphoma
We established an inbred strain of mouse called the spontaneous lymphoma mouse strain (SL/Kh) 
as a model of murine leukemia virus (MLV) integration-induced B-LBL lymphomagenesis. In the 
experimental model, transgenic mice carrying chimera genes, such as Emu-myc mice, MT-BCR-ABL 
Figure 1. Scheme of B-cell development stage and IL-7R/pre–B-cell receptor (BCR) expression. CLP, common lymphocyte 
precursor.
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mice, [6, 7], and TEL/AML1 mice rapidly develop pre-B LBL [8–10]. Unlike these models, the SL/Kh 
mouse develops spontaneously in the absence of artificially introduced gene mutation; however, 
Zfp521 is the gene that is spontaneously and constitutively mutated by MLV insertion after the birth 
[11, 12].
These mice share MLV with AKR-strain mice that are susceptible to T lymphoma [13, 14]. 
SL/Kh mice were found to have multiple copies of the pathogenic endogenous proviral 
genome that are genetically transmitted through the germ line on chr 7 [12, 15]. A type 
of MLV expressed from this provirus infects the hematopoietic cells and MLV genome is 
somatically re-integrated into the host cell genome. Subsequently, B-LBL spontaneously 
develops with a high frequency of 95% after 6 months of birth. These lymphoma cells 
are positive for lambda5 and Vpreb, which are a part of the pre-BCR. Myeloid leukemia, 
mature B-cell lymphoma, and T-cell lymphoma are known to occur in the inbred strain 
of mouse [16]. Such high occurrence of identical B-lymphoblastic lymphoma/leukemia 
phenotypes has not been reported in other mice. The initial growth of pre–B cells in SL/
Kh was proven to be independent of the provirus integration, but dependent on the bone 
marrow pre-B1 (Bomb1) locus that includes BANK1 and the enpep gene that involves a 
glutamyl aminopeptidase (BP-1) (Mm.1193, UniGeneID) [17]. Clinically, the mice present 
with hepatosplenomegaly in which pre–B LBL invades via the portal tract and replace 
the splenocytes. In addition, the spinal bone becomes deformed, because of bone struc-
ture remodeling. As described later, the identified signal cascade promoting the MLV 
proviral element gives the clue for understanding of the development of lymphomagen-
esis through upregulation of signaling pathways and can serve as a model of clinical 
intervention by administration of anti-tumor drugs because of stable susceptibility for 
lymphomagenesis.
2.2. Flow cytometry analysis of B-LBL experimental lymphomas
Flow cytometric analysis is the one of the most important methods for analyzing pre–B cells. 
BP1, B220, IL-7R, CD24, and CD43 are the classical phenotypic markers of pre–B cells as well as 
λ5 and Vpreb. These markers were available for Hardy’s classification for murine B cell lineage 
(Figures 2 and 3) [18, 19]. These markers are a little different from those that are used for the clas-
sification of human B-cell lineages, because B220 , BP-1, CD43, and CD24 are included.
2.3. Genetic background of pre–B lymphomagenesis
Bomb1, a quantitative trait locus (QTL), on Mus musculus (MMU) chromosome 3 is respon-
sible for pre–B-cell expansion [20, 21] (Figure 4). In analysis of the congenic mice carrying 
SL/Kh alleles of Bomb1, polyclonal expansion of pre–B cells is observed. BANK1, an adaptor 
molecule of pre-BCR, is located near the Bomb1 locus. We generated a congenic strain, NFS.
SL/Kh-Bomb1 mice, with the replacement of this locus with SL/Kh Bomb1, without pre–B-
induced provirus. The congenic mice showed pre–B-cell expansion, but pre–B lymphoma-
genesis were not observed. Therefore, the pre–B-cell lymphomagenesis is probably induced 
by multiple genes, including MLV integration into the proto-oncogenes. Notably, this locus is 
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also  susceptible to high-frequency microsatellite instability (MSI) in the pre–B LBL in mouse 
chromosome 3 including the Bomb1 [17] (Figure 5). MSI is confirmed at ≥2 markers in DNA 
derived from tumor tissues in 93.7% of SL/Kh mice. To date, there have been only few sys-
tematic analyses of MSI and our data are significant in the hematopoietic tumors. Irregular 
deletion and insertion are observed within Bomb1 in the course of lymphoma tissue with a 
high frequency.
Figure 3. Ig recombination and B-cell development stage. VpreB and λ5 are components of surrogate light change in the 
pre-BCR. Igα and β are adaptor molecules that are identical to CD79a and CD79b. Pre-BCR is tentatively formed in the 
stage of large pre-B.
Figure 2. Surface phenotypic markers and Hardy’s classification. BP-1 and IgM are notable markers. Fr., fraction.
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3. Upregulation of proto-oncogenes in pre–B lymphomas
Retroviral tagging, such as MLV insertion, is considered as a useful method for the identifica-
tion of proto-oncogenes. RTCGD (Retrovirus and Transposon-tagged Cancer Gene Database, 
http://variation.osu.edu/rtcgd/) is one of the established registration systems of MLV integra-
tion, and many genes were identified as the common integration site (CIS) [16].
Figure 4. Bomb1 locus and microsatellite markers on chromosome 3.
Figure 5. Microsatellite instability in the genome of lymphoma cells in the lane of healthy lymph node tissue [17]. 
Dinucleotide CT is deleted in the lymphoma genomes.
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There many identified genes that are involved in the development of hematopoietic tumors. 
We summarize the signaling pathways that are associated with the target genes as described in 
the subsequent text.
3.1. IL-7R-signaling pathway and Stat5a
In both humans and mice, the IL-7R (also known as CD127) is expressed by early B-cell pro-
genitors, and signaling via IL-7Rα activates signal transducer and activator of transcription 5 
(STAT5) and drives pro-B-cell proliferation, while inhibiting Igκ recombination [22, 23].
Stat5a gene is one of the target genes of MLV integration in B-cell tumors (Table 1). The 
encoded STAT5 protein is a member of the signal inducer and activator of transcription (STAT) 
family and includes STAT5A and STAT5B subtypes. They are encoded by separate genes—the 
proteins are 90% identical at the amino acid level. These encoding genes are both targets of 
MLV. STAT5 proteins are activated by Janus kinases (JAKs) associated with transmembrane 
receptors such as interleukin receptor. Because, deletion of Stat5a and Stat5b arrests B-cell 
development at the pre–pro-B cell stage [24].
Binding of the cytokine ligands to these receptors on the outside of the cell activates the JAK3 
[25]. Subsequently, the activated kinases add a phosphate group to tyrosine residues (Y449) on 
the IL-7Rα chain of the receptor. STAT5 then binds to these phosphorylated tyrosines. STAT5 is 
subsequently phosphorylated by the JAK3. The phosphorylated STAT5 forms either homodi-
mer. Phosphorylated STAT proteins have the potential to form a dimer that can translocate 
into the nucleus and upregulate transcriptional activity by binding to the gamma interferon 
activation site palindromic (GAS) element in the promoters of the target genes. The targets 
encode c-Myc, Pim-1 [26], Bcl-xL, and Cyclin D1 [27], which promote proliferation and apoptosis 
in hematopoietic cells [28]. STAT5A, in particular, contributes to IL-7–induced B-cell precursor 
expansion. IL-7R is highly expressed in pre–B cells during Igh recombination, and therefore 
Stat5a has been one of the responsible molecules for Igh recombination [29]. Attenuation of 
IL-7R signaling in both human and mouse pre–B cells is associated with the expression of RAG1 
and RAG2.







MHC class heavy chain 100 2
Table 1.  Common integration site.
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A comparison of the phenotype of SL/Kh lymphomas showed that when the Stat5a was highly 
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 recombination, are completed. On the other hand, Stat5a-high 
clones highly express λ5 but low for Vpreb; by contrast, Stat5a-low clones were constitutively 
high for both λ5 and Vpreb. In summary, the Stat5a-high lymphoma clones are more immature 
than other lymphomas. Stat5a may contribute to the lymphomagenesis at the immature stage 
of B cells [29].
3.2. Zfp521 and pre-BCR pathway
The Zfp521 gene was identified at the MLV integration site in the genomes of B-cell lympho-
mas in the AKXD mouse strain [30, 31]. This gene is also the most frequent integration site as 
well in the genome of pre–B-cell lymphoma in SL/Kh mice (Figure 6) and is related to imma-
ture B lymphomagenesis [11, 32]. Zfp521 expression contributes to neural crest formation and 
the development of adipose cells, chondrocytes [33, 34], bone [34–36], and neural crest [35]. 
Recently, we reported that ZFP521 regulates and activates pre–B-cell receptor signal path-
ways, and it modulates the IL-7-signaling pathway [11].
The pre-BCR is expressed on large pre–B cells in which Igh recombination is completed. In the 
initiation of Igκ or Igλ gene rearrangement, signals of the IL-7 receptor gradually attenuate 
in pre–B cells, and B-cell maturation proceeds. Although both the IL-7R and the pre-BCR are 
required for murine B-cell lymphopoiesis, the orchestration of signal pathways has remained 
controversial. The responsiveness to IL-7 and stimulation through pre-BCR controls the 
development of pre–B cells into mature B cells [22, 23]. During the development of pro-B cells 
into pre–B cells, IL-7 signaling is the major mediator. The mature BCR replaces the pre-BCR. 
Zfp521 is expressed from professional pre–B cell of Fraction A (Fr. A) to Fr. B-C according 
to Hardy’s classification. In this pre–B stage, Zfp521 may interact with adaptor molecules of 
Cd79a/b such as BANK1, Blnk, and Btk. Zfp521 may play as a transcriptional factor, because 
of a stimulation of this gene expression in a cell line, and the signal was located in the nucleus 
[30]. However, the binding motif on DNA is not clearly identified. The IL-7 receptor pathway 
interfered with Vpreb stimulation through the upregulation of BANK1 near or on Bomb1 by 
ZFP521. BANK1 is disrupted by IL-7R signaling and interacts with phospholipase gamma 
2 [37]. In fact, BANK1-PLCg2 binding is enhanced by B-lymphocyte kinase (BLK) [37]. 
Therefore, complicated per-BCR adaptors are hypothesized (Figure 7).
Cyclin D3 and Cyclin D2 are upregulated by overexpression of the ZFP521 gene. Pre-BCR 
was shown to mediate Ras-MEK-extracellular signal-regulated kinase (ERK)-signaling 
pathway activation and light-chain recombination by silencing Cyclin D3 [38].
In humans, the fusion of the Pax5, which is essential for pre–B-cell development gene, exon 
7 to ZFP521 exon 4, has been observed in pre–B-cell acute lymphocytic leukemia by genome-
wide analysis of genetic alterations [39]. Dysregulation of ZFP521 gene leads to pre–B-cell 
lymphomagenesis through the activation of pre–B-cell-specific molecular-signaling pathways 
[11]. Therefore, ZFP521 could be considered as a target for molecular-targeted therapy.
Signal Pathway in Precursor B-Cell Lymphoblastic Leukemia/Lymphoma
http://dx.doi.org/10.5772/intechopen.68892
39
3.3. FLT3 signaling and LBL development via Fiz1
(a) Fms like tyrosine kinase 3 (FLT3) belongs to the immunoglobulin superfamily CD135 
also known as fetal liver kinase-2 (Flk2). This protein is the receptor for the cytokine Flt3 
ligand (FLT3L). FLT3 is a type III receptor tyrosine kinase with five immunoglobulin-like 
motifs in the extracellular region. In the intracellular region, a tyrosine kinase region (TK) 
and a C-terminal region composed of a juxtamembrane region (JM) and a kinase insert are 
contained. This protein is constitutively expressed in the hematopoietic stem and progenitor 
cells. On the other hand, the ligands that bind to the FLT3 receptor (FL) are produced in bone 
marrow stromal cells. FL directly stimulates hematopoietic stem cells or together with other 
cytokines and plays an important role in its survival, proliferation, and differentiation. FLT3 
is also one of the critical developmental factors for B- and T-lymphocyte development [40].
(a)
(b)
Figure 6. (a) Schematic representation of MLV integration in Zfp521 in SL/Kh mice. By the age of 2–3 months, the MLV 
host cell has grown in BM, and the endogenous MLV integrates into the genome of the host lymphocytes. The host cells 
clonally grow with higher expression of the Zfp521 gene. The tandem box in the upper scheme represents long terminal 
repeat (LTR) of the provirus.
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In the absence of FL, FLT3 remains in the inactivated monomeric form. When FLT3 binds to 
FL, a ternary complex is formed in which two FLT3 molecules are bridged by one (homodi-
meric) FLT3L. Ligand binding promotes conformational changes in FLT3 for dimerization, phos-
phorylation, and association with adaptor proteins such as Fiz1. The complex formation brings 
the intracellular domains close to each other, promoting initial phosphorylation of the kinase 
domain. Activated dimeric FLT3 transduces signals to the downstream effectors. In the patho-
genesis analysis, FLT3 is expressed on the cell surface of most AML and ALL cells through prolif-
eration activation and apoptosis suppression, which are caused by the stimulation of FL [41–43].
Internal tandem duplications (ITDs) occur in exon 14 or 15 of the JM, which are located directly 
between the transmembrane domain (TM) and tyrosine kinase region TK1 [44]. Insertions, 
deletions, and point mutations are frequently found in exon 20 of another tyrosine kinase 
region TK2.The functional kinase region is kept, and only the JM region is elongated. ITDs 
probably promote ligand-independent dimerization and activation of FLT3 by changing the 
conformation of the expressed receptor [44, 45]. In addition, another mutation was identified 
within the kinase activation loop, a part of the functional core. The conformational changes 
associated with ITDs might change the structure of the receptor such that unique adaptor 
proteins such as Fiz1 can now dock.
(b) Fiz 1: This gene encodes the zinc finger protein, which interacts with a receptor tyrosine 
kinase involved in the regulation of hematopoietic and lymphoid cells. This gene product 
also interacts with a transcription factor that regulates the expression of rod-specific genes in 
the retina. Fiz1 binds to the catalytic domain of Flt3 but not to c-Kit, Fms, or platelet-derived 
Figure 7. Pre-BCR pathway and Zfp521.
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growth factor receptor [46, 47]. In a part of B-LBL in SL/Kh, Fiz1 is upregulated by MLV 
genome insertion and interaction with IL-7R pathway is observed. FLT3 stimulation enhances 
IL-7R signaling cascade by promotion of Stat5a phosphorylation [48]. Therefore, FLT3 and 
IL-7R signal pathways interact with each other in the development of B-LBL/ALL.
3.4. CD43 and Hipk2 in the development of B-LBL/ALL
HIPK2 is a conserved serine/threonine nuclear kinase that interacts with homeodomain 
transcription factors. This protein interacts with the cytoplasmic domain of CD43, which 
is expressed on immature pro- to pre–B cells, Fr. A-C in Hardy classification. In this imma-
ture stage, IL-7R is highly expressed and the CD43 pathway may interact with IL-7R path-
way recruiting STAT5A. Hipk2 promotes Wnt signaling by stabilizing beta-catenin [49]. Hipk2 
interacts with lymphoid-enhancing factor 1, which acts as a transcriptional factor, promoting 
c-Myc and cyclin D1 expression [50]. CD43 is an E-selectin counter-receptor highly expressed in 
human pre–B-cell leukemia NALL-1 cell line [51]. In our study, CD43 cross-linking resulted in 
an increase in STAT5A phosphorylation, when IL-7 was supplied. CD43 signaling may enhance 
the IL-7R signal pathway [48, 52].
4. Signaling pathway network responsible for pre–B lymphomagenesis
Probably, multiple genes are related to the activation of IL-7R-signaling pathway. Hipk2 and 
Fiz 1 are candidates of interaction with IL-7R pathway as well as Stat5. Considering the acti-
vation of FLT3 pathway in AML, B-LBL may share the activation pathway with AML [10]. 
We propose a scheme of interactions among the IL-7-, CD43-, and FLT3-signaling pathways 
(Figure 8) [48]. Thus, we hypothesize that these three pathways form an interacting network 
Figure 8. Signaling pathway network in association with IL-7R.
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and affect B-LBL development. By contrast, pre-BCR pathway is activated by Zfp521 through 
the upregulation of BLNK [53, 54], BANK1 [37], Btk, and other pre–BCR-related molecules. 
Pre-BCR pathway has been considered to contribute to pre–B-cell development rather than to 
proliferation. Therefore, although stimulation of pre-BCR promotes pre-B cell proliferation, 
Zfp521 may not directly contribute to lymphomagenesis, but contribute to the stabilization of 
phenotype of B-LBL. Or interaction with IL-7R and pre-BCR may promote aberrant prolifera-
tion or development. Further research is required for precise understanding of the interaction 
between these two pathways in B-cell development.
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